Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time. This event presents an opportunity for investors and industry professionals to gain insights into Seer's innovative platform and business strategies.
Interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website after the conference concludes. This participation underscores Seer's commitment to engaging with the investment community and showcasing its advancements in the proteomics field.
Seer, Inc. (Nasdaq: SEER), a leading life sciences company, has appointed Dr. Nicolas Roelofs to its Board of Directors. Dr. Roelofs brings over 35 years of operational and advisory experience in healthcare, life science tools, and diagnostics companies. His extensive background includes serving as President of the Life Sciences Group at Agilent Technologies and holding leadership positions at Bio-Rad Inc. and Stratagene Inc.
Dr. Roelofs expressed excitement about working with Seer, highlighting the company's unique capability to enable deep, unbiased proteomic analysis at unprecedented scale, speed, and robustness. He aims to leverage his industry experience to accelerate the adoption of Seer's Proteograph Product Suite and advance proteomics research.
Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management team is set to engage in a fireside chat on Wednesday, August 14th at 3:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website following the conference, ensuring widespread access to this important corporate update.
Seer Inc. (Nasdaq: SEER) reported its Q2 2024 financial results, highlighting a revenue of $3.1 million, a 23% decrease from the previous year. The company launched its Seer Technology Access Center (STAC) in Europe and published customer papers in Nature journals. Despite macroeconomic challenges, Seer expanded its commercial team and focused on reducing barriers to its proteomics technology. Key financials include:
- Gross profit: $1.7 million with a 56% margin
- Operating expenses: $28.8 million, down 5% year-over-year
- Net loss: $22.9 million
- Cash, equivalents, and investments: $344.6 million
Seer revised its 2024 revenue guidance to $13-$15 million, down from the previous $16-$18 million range.
Seer, Inc. (Nasdaq: SEER), a prominent life sciences company specializing in proteomics, has announced its plans to release second quarter 2024 financial results on Thursday, August 8, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors and interested parties can access the live audio webcast through the Investor section of Seer's website at investor.seer.bio. An archived replay of the webcast will be made available on the company's website following the event for those unable to attend the live presentation.
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s technology allows comprehensive profiling of astronauts' physiological responses, aiding precision medicine and biomarker discovery. The studies include a substantial dataset from multiple space missions and highlight the Proteograph XT Assay Kit’s capabilities in detecting over 60,000 peptides and 8,000 proteins in plasma samples.
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample. The study, conducted across 77 clinical sites in the U.S., showcases the combined power of Seer and Thermo Fisher's technologies in early cancer detection. The findings will be presented at the ASMS Conference on June 6.
Seer, Inc. (Nasdaq: SEER), a life sciences company, reported Q1 2024 financial results. Achieved $3.1M in revenue, expanded STAC program to Europe, validated Proteograph Product Suite, launched Insights Grant Program, authorized $25M share repurchase program. Experienced a 24% revenue decrease primarily from product and related party revenue. Operating expenses decreased by 10%. Net loss was $20.7M. Cash position at $359.2M. Board authorized $25M share repurchase program. Full year revenue guidance for 2024 is $16-18M.
Seer, Inc. (Nasdaq: SEER) has launched a new Seer Technology Access Center in Bonn, Germany, to provide European life sciences researchers with access to the Seer Proteograph™ Product Suite and mass spectrometry technologies. The facility aims to support unbiased proteomic studies, accelerate biomarker discovery, and drug development. The European STAC will offer programs to enhance the availability of state-of-the-art proteomics technologies and assist researchers in expanding their research scope.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
